Intel unveils its first AI-driven neural network chip

Agencies

August 21, 2019

San Francisco, Aug 21: Intel has unveiled its first high-performance Artificial Intelligence (AI)-driven neural network chip "Nervana" to meet the growing high-speed computing and robotics demand.

The chip-maker showcased the Nervana neural network processors, with the NNP-T for training and the NNP-I for inference at the "Hot Chips 2019" conference at Stanford University in California on Tuesday.

"To get to a future state of 'AI everywhere,' we'll need to address the crush of data being generated and ensure enterprises are empowered to make efficient use of their data, processing it where it's collected when it makes sense and making smarter use of their upstream resources," said Naveen Rao, Intel Vice President and General Manager, Artificial Intelligence Products Group.

Built from the ground up to train deep learning models at scale, Intel Nervana NNP-T (Neural Network Processor) pushes the boundaries of deep learning training.

It is built to prioritise two key real-world considerations: training a network as fast as possible and doing it within a given power budget.

This deep learning training processor is built with flexibility in mind, striking a balance among computing, communication and memory, said Intel.

Intel Nervana NNP-I, or Springhill, is purpose-built for inference and is designed to accelerate deep learning deployment at scale, introducing specialised deep learning acceleration while leveraging Intel's 10nm process technology with Ice Lake cores to offer industry-leading performance.

Additionally, the Intel Nervana NNP-I offers a high degree of programmability without compromising performance or power efficiency.

"Data centres and the cloud need to have access to scalable general purpose computing and specialized acceleration for complex AI applications," said Rao.

Comments

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

Lung cancer rates are rising in young women

Agencies

February 6,2020

Researchers have found the rates of lung cancer are higher in young women than men.

The study, published in the journal Pediatrics, examined lung cancer rates in young adults in 40 countries across five continents and uncovered a trend of higher lung cancer rates in women compared with men in recent years.

The emerging trend was widespread, affecting countries across varied geographic locations and income levels.

The changes appeared to be driven by a rising rate of adenocarcinoma lung cancer among women, said the study researchers from University of Calgary in Canada.

Lung cancer rates have been higher among men than women because men started smoking in large numbers earlier and smoked at higher rates; however, recent studies have reported converging lung cancer incidence rates between sexes.

Among men, age specific lung cancer incidence rates generally decreased in all countries, while in women the rates varied across countries with the trends in most countries stable or declining, albeit at a slower pace compared to those in men.

For the findings, lung and bronchial cancer cases between 30-64 age group from 1993-2012 were extracted from cancer incidence in five continents.

The study found the higher emerging rates of lung cancer in young women compared to young men.

According to the researchers, future studies are needed to identify reasons for the elevated incidence of lung cancer among young women.

Comments

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

No evidence suggests BCG vaccine can protect against COVID-19: WHO

Agencies

April 14,2020

There is no evidence that the Bacille Calmette-Guerin (BCG) vaccine, which is primarily used against tuberculosis, protects people against infection with the novel coronavirus, the World Health Organization (WHO) said.

The WHO therefore didn't recommend BCG vaccination for the prevention of COVID-19 in the absence of evidence, according to its daily situation report on Monday, Xinhua news agency reported.

"There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance remains unknown," WHO stated.

Two clinical trials addressing the question are underway, and WHO will evaluate the evidence when it is available, it noted.

BCG vaccination prevents severe forms of tuberculosis in children and diversion of local supplies may result in an increase of disease and deaths from the tuberculosis, it warned.

Comments